WallStSmart

Amrize Ltd (AMRZ)vsCemex SAB de CV ADR (CX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cemex SAB de CV ADR generates 39% more annual revenue ($16.54B vs $11.91B). AMRZ leads profitability with a 9.7% profit margin vs 2.7%. CX appears more attractively valued with a PEG of 0.39. CX earns a higher WallStSmart Score of 54/100 (C-).

AMRZ

Hold

49

out of 100

Grade: D+

Growth: 4.0Profit: 5.0Value: 5.3Quality: 4.8
Piotroski: 3/9

CX

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 5.0Value: 7.7Quality: 4.8
Piotroski: 6/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMRZOvervalued (-6.1%)

Margin of Safety

-6.1%

Fair Value

$55.53

Current Price

$52.89

$2.64 premium

UndervaluedFair: $55.53Overvalued
CXUndervalued (+26.4%)

Margin of Safety

+26.4%

Fair Value

$17.58

Current Price

$13.11

$4.47 discount

UndervaluedFair: $17.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMRZ1 strengths · Avg: 8.0/10
Price/BookValuation
2.2x8/10

Reasonable price relative to book value

CX2 strengths · Avg: 10.0/10
PEG RatioValuation
0.3910/10

Growing faster than its price suggests

Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

AMRZ4 concerns · Avg: 3.8/10
P/E RatioValuation
27.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

EPS GrowthGrowth
3.6%4/10

3.6% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

CX4 concerns · Avg: 2.5/10
Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
2.7%3/10

2.7% margin — thin

EPS GrowthGrowth
-66.4%2/10

Earnings declined 66.4%

Altman Z-ScoreHealth
1.472/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMRZ

The strongest argument for AMRZ centers on Price/Book. PEG of 1.38 suggests the stock is reasonably priced for its growth.

Bull Case : CX

The strongest argument for CX centers on PEG Ratio, Price/Book. Revenue growth of 10.1% demonstrates continued momentum. PEG of 0.39 suggests the stock is reasonably priced for its growth.

Bear Case : AMRZ

The primary concerns for AMRZ are P/E Ratio, Revenue Growth, EPS Growth.

Bear Case : CX

The primary concerns for CX are Return on Equity, Profit Margin, EPS Growth. Thin 2.7% margins leave little buffer for downturns.

Key Dynamics to Monitor

CX is growing revenue faster at 10.1% — sustainability is the question.

CX generates stronger free cash flow (31M), providing more financial flexibility.

Monitor BUILDING MATERIALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CX scores higher overall (54/100 vs 49/100) and 10.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amrize Ltd

BASIC MATERIALS · BUILDING MATERIALS · USA

Amrize Ltd (AMRZ) is a cutting-edge technology firm revolutionizing the digital health and wellness sector by leveraging advanced technologies and data-driven solutions to enhance healthcare delivery. Focused on improving patient outcomes and expanding healthcare accessibility, Amrize is committed to extensive research and development that caters to the escalating demand for scalable health innovations. Its strategic initiatives and robust product offerings position the company as a significant contributor to the transformation of modern healthcare systems, making it a compelling investment opportunity in an evolving market landscape.

Visit Website →

Cemex SAB de CV ADR

BASIC MATERIALS · BUILDING MATERIALS · USA

CEMEX, SAB de CV, produces, markets, distributes and sells cement, ready-mix concrete, aggregates, clinker and other construction materials worldwide. The company is headquartered in San Pedro Garza Garca, Mexico.

Want to dig deeper into these stocks?